Prescient Therapeutics is developing novel personalised therapies against a range of cancers – Small Caps
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from...
We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16...
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.